Patent Watch: Have the Biosimilar Floodgates Been Opened in the United States?
30 April 2015
Partners Courtenay Brinckerhoff and Kristel Schorr contributed an article to Nature Reviews, “Patent Watch: Have the Biosimilar Floodgates Been Opened in the United States?” on April 30, 2015. The article discussed the first US Food and Drug Administration’s first approval of a biosimilar product and the regulatory hurdles products must clear before entering the US market.
Author(s)
Related Insights
07 October 2024
Health Care Law Today
Reimagining Home-Based Cancer Care: Key Legal and Regulatory Considerations
Turbocharged during the COVID-19 pandemic, evolving technology, enhanced reimbursement modalities and increased regulatory flexibility are creating new opportunities to offer acute-level oncology care to patients in their own homes.
21 October 2024
Events
Legal Overview of the BIOSECURE Act
Foley special counsel John Strom is speaking in the Association for Accessible Medicine’s GRx+Biosims 2024 conference in a panel titled “Legal Overview of the BIOSECURE Act” on October 21.
04 October 2024
Innovative Technology Insights
Decoding California’s Recent Flurry of AI Laws
Governor Newsom signed over 18 AI-related bills into law during September, impacting numerous industries.